Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Core Insights - Beyond Air, Inc. plans to report its financial results for the fiscal third quarter 2025, which ended on December 31, 2024, on February 10, 2025, after market close [1] - The company will host a conference call and webcast on February 10, 2025, at 4:30 PM ET to discuss the financial results [2] Company Overview - Beyond Air is a commercial stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to enhance the lives of patients with respiratory illnesses, neurological disorders, and solid tumors [3] - The company has received FDA approval for its LungFit® PH system, aimed at treating term and near-term neonates with hypoxic respiratory failure [3] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] - The company has partnered with The Hebrew University of Jerusalem to develop a pre-clinical program for treating autism spectrum disorder and other neurological disorders [3] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of NO for targeting specific solid tumors in pre-clinical settings [3]